Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Abstract Studies have reported reduced natural SARS-CoV-2 infection- and vaccine-induced neutralization against Omicron BA.4/BA.5 compared with earlier Omicron subvariants. We conducted a test-negative case–control study evaluating mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization with Omicron subvariants. The study included 30,809 SARS-CoV-2 positive and 92,427 SARS-CoV-2 negative individuals aged ≥18 years tested during 1/1/2022-6/30/2022. While 3-dose VE against BA.1 infection was high and waned slowly, VE against BA.2, BA.2.12.1, BA.4, and BA.5 infection was initially moderate to high (61.0%-90.6% 14-30 days post third dose) and waned rapidly. The 4-dose VE against infection with BA.2, BA.2.12.1, and BA.4 ranged between 64.3%-75.7%, and was low (30.8%) against BA.5 14-30 days post fourth dose, disappearing beyond 90 days for all subvariants. The 3-dose VE against hospitalization for BA.1, BA.2, and BA.4/BA.5 was 97.5%, 82.0%, and 72.4%, respectively; 4-dose VE against hospitalization for BA.4/BA.5 was 88.5%. Evaluation of the updated bivalent booster is warranted.
Ackerson Bradley K.、Qian Lei、Tubert Julia E.、Ku Jennifer H.、Choi Soon Kyu、Aragones Michael、Talarico Carla A.、Takhar Harpreet S.、Chavers Scott、Bruxvoort Katia J.、Sy Lina S.、Tseng Hung Fu、Paila Yamuna D.、Florea Ana、Qiu Sijia、Luo Yi、Lee Gina S.
Kaiser Permanente Southern CaliforniaKaiser Permanente Southern CaliforniaKaiser Permanente Southern CaliforniaKaiser Permanente Southern CaliforniaKaiser Permanente Southern CaliforniaKaiser Permanente Southern CaliforniaModerna, Inc.Kaiser Permanente Southern CaliforniaModerna, Inc.Kaiser Permanente Southern California||University of Alabama at BirminghamKaiser Permanente Southern CaliforniaKaiser Permanente Southern California||Kaiser Permanente Bernard J. Tyson School of MedicineModerna, Inc.Kaiser Permanente Southern CaliforniaKaiser Permanente Southern CaliforniaKaiser Permanente Southern CaliforniaKaiser Permanente Southern California
预防医学医药卫生理论医学研究方法
Ackerson Bradley K.,Qian Lei,Tubert Julia E.,Ku Jennifer H.,Choi Soon Kyu,Aragones Michael,Talarico Carla A.,Takhar Harpreet S.,Chavers Scott,Bruxvoort Katia J.,Sy Lina S.,Tseng Hung Fu,Paila Yamuna D.,Florea Ana,Qiu Sijia,Luo Yi,Lee Gina S..Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5[EB/OL].(2025-03-28)[2025-08-02].https://www.medrxiv.org/content/10.1101/2022.09.30.22280573.点此复制
评论